Atomi Financial Group Inc. Acquires 1,269 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Atomi Financial Group Inc. increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 81.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,829 shares of the medical research company’s stock after purchasing an additional 1,269 shares during the period. Atomi Financial Group Inc.’s holdings in Thermo Fisher Scientific were worth $1,750,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Campbell & CO Investment Adviser LLC bought a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at about $382,000. MGO One Seven LLC boosted its stake in Thermo Fisher Scientific by 22.2% during the fourth quarter. MGO One Seven LLC now owns 3,193 shares of the medical research company’s stock valued at $1,695,000 after buying an additional 581 shares during the last quarter. Vista Investment Management increased its stake in Thermo Fisher Scientific by 4.8% in the 4th quarter. Vista Investment Management now owns 5,001 shares of the medical research company’s stock worth $2,654,000 after acquiring an additional 228 shares during the last quarter. Oribel Capital Management LP purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $59,555,000. Finally, Ethic Inc. boosted its position in shares of Thermo Fisher Scientific by 8.9% during the 4th quarter. Ethic Inc. now owns 32,545 shares of the medical research company’s stock valued at $17,274,000 after acquiring an additional 2,671 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $180,255.00. Following the completion of the transaction, the executive vice president now owns 17,887 shares in the company, valued at approximately $10,747,403.95. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the transaction, the executive vice president now owns 17,887 shares in the company, valued at approximately $10,747,403.95. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 23,084 shares of company stock valued at $14,094,292. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.6 %

Shares of NYSE:TMO opened at $595.14 on Wednesday. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $627.88. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. The stock has a market cap of $227.34 billion, a price-to-earnings ratio of 38.17, a PEG ratio of 3.83 and a beta of 0.77. The business has a 50-day moving average price of $609.35 and a 200-day moving average price of $582.90.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.13 by $0.24. The company had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The firm’s quarterly revenue was down 1.4% on a year-over-year basis. During the same period in the previous year, the firm posted $5.15 earnings per share. Equities analysts predict that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. Thermo Fisher Scientific’s payout ratio is 10.01%.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Wells Fargo & Company assumed coverage on shares of Thermo Fisher Scientific in a report on Tuesday, August 27th. They issued an “overweight” rating and a $670.00 price target for the company. Robert W. Baird increased their price target on Thermo Fisher Scientific from $620.00 to $632.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. TD Cowen upped their target price on Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Bank of America lifted their price objective on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a report on Monday, September 16th. Finally, Raymond James lifted their price target on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $653.72.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.